74 results about "Lysophosphatidylcholine" patented technology

The invention relates to the field of biological medicine, and discloses application of LPC, PC and AA in children sepsis diagnosis and prognosis product development. According to the invention, a high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS) technology is used, plasma samples of a child sepsis patient and a healthy control group are compared, the relationship between lipidome change and pSOFA score is analyzed, and specific lipid molecules closely related to disease severity and prognosis are identified. According to the invention, the following lipid molecules are highlighted as key biomarkers: lysophosphatidylcholine (LPC), phosphatidylcholine (PC) and arachidonic acid (AA). The change of the lipid molecules is closely related to the physiological state of a child sepsis patient, and the lipid molecules can be used for early diagnosis and evaluation of the state of the child sepsis, so that the treatment effect and the accuracy of prognosis evaluation are improved, and a new treatment strategy and a new management method are provided for clinic.

The invention discloses a metabolic marker composition for early diagnosis of cervical cancer as well as a screening method and application of the metabolic marker composition. The metabolic marker composition for early diagnosis of cervical cancer comprises pyroglutamic acid, lysophosphatidylcholine 20: 3, phosphatidylcholine 32: 2 and pyruvic acid. The metabolic marker composition provided by the invention has relatively high sensitivity and specificity when being used for early-stage cervical cancer diagnosis, can realize accurate screening of early-stage cervical cancer, and provides important help for prevention of cervical cancer and reduction of morbidity. Meanwhile, when the metabolic marker composition is used for early-stage cervical cancer diagnosis, operation is easy, a sample is convenient to obtain, cost is low, invasion is avoided, a patient can receive detection more conveniently, rapidly and safely, and the metabolic marker composition is more suitable for large-scale population screening and regular tracking in areas with shortage of medical resources.

The invention discloses a permeation enhancing composition as well as a preparation method and application thereof, and relates to the technical field of cosmetics. The invention provides a permeation enhancing composition. The permeation enhancing composition is prepared from the following components in parts by weight: 0.01 to 0.3 part of conopeptide, 0.1 to 8 parts of lysolecithin and 0.1 to 8 parts of compound plant extract, the composite plant extract is prepared from the following raw materials: radix angelicae sinensis, flos caryophylli, radix salviae miltiorrhizae and radix glycyrrhizae. According to the transdermal penetration enhancer disclosed by the invention, the lysophosphatidylcholine and the composite plant extract with specific dosages are cooperated to influence skin proteins and lipids at the same time and break through two ways of transcellular membrane penetration and intercellular lipid penetration, so that the transdermal absorption intradermal cumulant of conopeptide is effectively increased, and compared with a traditional penetration enhancer, the transdermal penetration enhancer disclosed by the invention has an obvious improvement effect.

Provided herein are methods and materials for using organisms (e.g., engineered yeast strain-derived) to generate lipid compositions which can modulate cellular aging, extend lifespan, and / or modulate gut homeostasis in a subject. The lipid compositions contain at least twelve of the lipids selected from a phosphatidylethanolamine (PE); a lysophosphatidylethanolamine (LPE); a diacylglycerol (DG); a monoglyceride (MG); an acyl carnitine (AcCa); a phosphatidic acid (PA); a phosphatidylglycerol (PG); a lysophosphatidylcholine (LPC); a triacylglycerol (TG); a cholesterol ester (ChE); a wax ester (WE); a phosphatidylserine (PS); a phosphatidylcholine (PC); a phosphatidylinositol (PI); a ceramide (Cer); and a lysophosphatidylserine (LPS).

The present disclosure relates to lipid nanoparticles comprising a lysophosphatidylcholine (LPC) compound and at least one further lipid, and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells. The present disclosure also relates to compositions comprising lipid nanoparticles comprising a LPC and at least on further lipid, in which the compositions comprise one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.

The invention provides a metabolic marker for auxiliary diagnosis of schizophrenia, a construction method and application. Wherein the metabolic marker comprises lysophosphatidylcholine (LPC) (17: 0 / 0: 0), oleamide, lysophosphatidyl ethanolamine LysoPE (18: 0 / 0: 0), palmitamide, lysophosphatidyl ethanolamine LysoPE (0: 0 / 20: 4), lysophosphatidyl ethanolamine LysoPE (22: 6 / 0: 0), p-methylphenol sulfate, lactic acid, 3-hydroxybutyric acid, lysophosphatidyl ethanolamine LysoPE (18: 2 / 0: 0), lysophosphatidyl ethanolamine LysoPE (16: 0 / 0: 0) and sphingosine 1-phosphate. By utilizing the metabolic marker, auxiliary diagnosis of schizophrenia can be rapidly and accurately completed in the early stage of disease attack.

The invention provides a metabolic marker for auxiliary diagnosis of schizophrenia, a construction method and application. Wherein the metabolic marker comprises lysophosphatidylcholine (LPC) (17: 0 / 0: 0), oleamide, lysophosphatidyl ethanolamine LysoPE (18: 0 / 0: 0), palmitamide, lysophosphatidyl ethanolamine LysoPE (0: 0 / 20: 4), lysophosphatidyl ethanolamine LysoPE (22: 6 / 0: 0), p-methylphenol sulfate, lactic acid, 3-hydroxybutyric acid, lysophosphatidyl ethanolamine LysoPE (18: 2 / 0: 0), lysophosphatidyl ethanolamine LysoPE (16: 0 / 0: 0) and sphingosine 1-phosphate. By utilizing the metabolic marker, auxiliary diagnosis of schizophrenia can be rapidly and accurately completed in the early stage of disease attack.

The invention provides an LPC liposome preparation for brain-targeted delivery of chemotherapeutic drugs as well as a preparation method and application of the LPC liposome preparation. The LPC liposome preparation comprises L-alpha-lysophosphatidylcholine, egg yolk lecithin and cholesterol, and the mass of the L-alpha-lysophosphatidylcholine is 5%-30% of the total mass of the L-alpha-lysophosphatidylcholine, the egg yolk lecithin and the cholesterol. The constructed LPC lipidosome can accelerate endocytosis of the lipidosome in bECs, and the lipidosome is transferred to an endosome recovery way by up-regulating p62, so that the lipidosome is prevented from entering a lysosome degradation way, and the transendocytosis efficiency is remarkably improved.

The invention provides a blood marker for distinguishing lung cancer and non-lung cancer diseases and application of the blood marker, and belongs to the technical field of biomarkers. The blood marker for distinguishing lung cancer and non-lung cancer diseases comprises at least five metabolites as follows: phosphatidylethanolamine (36: 4), lysophosphatidylcholine 18: 1e, phosphatidylethanolamine 38: 7e, sphingomyelin d38: 5, dodecanedioic acid, N-acetylputrescine, L-glutamyl-L-glutamine, hippuric acid, trans-cyclohexane-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3-triazole-1, 3, 4- The compound is prepared from 1, 2-dicarboxylic acid, glycochenodeoxycholic acid, allantoic acid, L-valine, methyleucine and 4-guanidinobutyric acid. A diagnosis model is constructed based on the blood marker, and the area under curve (AUC) is greater than 0.77, which indicates that the diagnosis result is accurate and reliable. The invention provides an effective marker for diagnosis of lung cancer and differential diagnosis of lung cancer and non-lung cancer diseases, greatly simplifies experimental operation, and has important clinical diagnosis significance.

The invention discloses a method for preparing 1-linoleoyl lysophosphatidylcholine from ganoderma lucidum, which takes ganoderma lucidum as a material, has the advantages of wide raw material source, simple preparation method and easy realization of industrial production, provides a new way for the development of 1-linoleoyl lysophosphatidylcholine, and also provides scientific guidance for the research and development of ganoderma lucidum functional health food.

The invention relates to the technical field of cock breeding, in particular to a biomarker, a preparation method and application thereof and a method for assisting in breeding cock semen quality identification. The biomarker comprises the following components: phosphatidylcholine, lysophosphatidylcholine, phosphatidyl ethanolamine, lysophosphatidyl ethanolamine, phosphatidylserine and lysophosphatidylserine. According to the invention, key markers can be rapidly detected from the semen so as to determine breeding suitable for liquid-state preservation of the semen and high-activity individuals. The artificial insemination interval time can be greatly prolonged, and long-time high-sperm active breeding cock individuals can be rapidly bred. The breeder cock breeding amount can be reduced, grains are saved, and breeding benefits are greatly improved.

The present application relates to the technical field of feed additive, and discloses a lactation-promoting functional feed for lactating sows containing high-efficiency plant lactogenic factors, which is made of the following raw materials: sodium-based montmorillonite, fenugreek extract, motherwort extract, ion intensity regulator, lysophosphatidylcholine, tributyl citrate and high-purity silicon dioxide, and is prepared through the following steps: mixing and drying sodium-based montmorillonite with the ion intensity regulator to prepare a regulation carrier; adding fenugreek and motherwort extract and mixing them by strong shearing to form an active core; atomizing and spraying a mixture of lysophosphatidylcholine and tributyl citrate on the surface of the core to form a functional layer; and finally adding high-purity silicon dioxide and mixing uniformly to obtain the feed. Through the construction of the structure with ion-pretreated montmorillonite as the core and the functional layer as the shell, the present application realizes the protection, sustained release and efficient absorption of the active ingredients, and improves the bioavailability.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.

The invention belongs to the technical field of antiviral drugs for livestock and poultry, and discloses application of lysophosphatidylcholine and dihydromyricetin in preparation of drugs for treating or preventing porcine reproductive and respiratory syndrome virus infection. The CAS number of the lysophosphatidylcholine is 17364 to 16 to 8, and the CAS number of the dihydromyricetin is 27200 to 12 to 0. The applicant performs cell level and animal body level anti-infection research on the pharmaceutical composition, and finds that the pharmaceutical composition shows a remarkable anti-PRRSV effect in vivo and in vitro, can reduce proliferation of viruses in a pig body, reduces damage of PRRSV infection to lung tissues and organs, effectively controls adverse effects of PRRSV infection to the body, and has a remarkable anti-PRRSV effect. The clinical disease symptoms of the pigs in the PRRSV infection period can be weakened, and the porcine reproductive and respiratory syndrome can be prevented and controlled.

The present disclosure relates to compositions for expressing a constitutively active cyclic GMP-AMP synthase in a cell of a mammalian subject and their use for enhancing the immunogenicity of an mRNA vaccine. The mRNA may be encapsulated in a lipid nanoparticle (LNP) or may be complexed with a lipid (RNA-Lipoplex). The present disclosure also relates to compositions further comprising one or both of a lysophosphatidylcholine (LPC) compound and a pathogen-recognizing receptor agonist.

The invention relates to the non-therapeutical use of phosphatidylcholine and / or lyso- phosphatidylcholine for increasing the nutrient retention of at least one Long-Chain Fatty Acid (LCFA) in an animal or a human, or to a use of phosphatidylcholine and / or lyso- phosphatidylcholine for increasing the thermal stability of at least one Long-Chain 5 Unsaturated Fatty Acid (LC-UFA). The invention further relates to an ingestible composition, and a method of preparation of such a composition.

The invention discloses a biomarker combination for predicting the treatment effect of AK112 and application of the biomarker combination. The biomarker combination is prepared from APOE + KRT18-CCL20-macrophages, CD161 + CD8 + T cells, PDCD1, FGF2, diglyceride and lysophosphatidylcholine. Flow cytometry immunophenotypes (macrophage subgroups and T cell subgroups), plasma protein markers (PDCD1 and FGF2) and metabolic micromolecules (diglyceride and lysophosphatidylcholine) are combined to form a cross-omics prediction system, the combination can synchronously evaluate dual action mechanisms (immune activation and blood vessel regulation) of AK112, the technical bottleneck of single dimension of existing liquid biopsy is broken through, and the application prospect is wide. And a non-invasive dynamic monitoring tool is provided for accurately screening AK112 benefit people.

The invention relates to a vegan composition for promoting collagen production. The composition comprises from 4200 mg to 12500 mg of an amino acid blend, wherein the amino acid blend comprises glycin

This invention provides an application and method of lysophosphatidylcholine (LPC) in promoting early development of reconstructed embryos, belonging to the field of embryo engineering technology. The invention first prepares reconstructed embryos, then adds lysophosphatidylcholine to the culture system for culturing. Lysophosphatidylcholine effectively promotes early development of the reconstructed embryos; at an optimal concentration of 5 μM, the blastocyst development rate increases to 24.56%, providing a novel and operable biochemical intervention target to solve the problem of low reconstructed embryo culture efficiency. This invention not only fills the gap in our understanding of the mechanism of action of LPC in this field, but also achieves controllability and reproducibility of the technical solution through precise definition of the optimal concentration. It provides key parameters for establishing standardized culture procedures and provides a more solid foundation for downstream applications such as developmental biology research and disease model construction that rely on high-quality reconstructed embryos, significantly accelerating the process of related scientific discovery and application development.

The invention relates to an emulsifying agent characterized in that it comprises 5% to 30% by weight of lysophosphatidylcholine (LPC)-enriched phospholipids in a suitable vehicle. The invention also relates to the use of this emulsifying agent in the preparation of topical compositions, particularly cosmetics, and to said compositions themselves.

The application discloses a phospholipase A1 mutant and application thereof. In the application, the PLA1 mutant is obtained by modifying the PLA1, wherein compared with the wild-type PLA1, the optimal temperature of the PLA1 mutant remains unchanged, and the PLA1 mutant has higher phospholipase A1 activity between 40-50 DEG C; the optimal pH of the PLA1 mutant is changed from 3 to 8; the PLA1 mutant has high phospholipase activity at pH 3-9, and the phospholipase activity is higher than that of the wild-type PLA1 under the optimal condition; and the pH adaptability range of the PLA1 is widened. Therefore, the PLA1 mutant has better application prospect, and meets the requirement of the enzyme performance in phospholipid processing, and can be applied to oil degumming, production of lysophosphatidylcholine, and application in the fields of biology, food, medicine, beauty, agriculture and industry.

The invention discloses a detection method of lysophosphatidylcholine, which can realize good separation of lysophosphatidylcholine and other components in a preparation sample by optimizing a chromatographic column, adjusting a mobile phase and using isocratic elution, greatly shortens the operation time of a single needle, and improves the detection efficiency.

The invention belongs to the technical field of biological medicines, and particularly relates to application of lysophosphatidylcholine in treatment and / or repair of spinal cord injury. The invention discloses application of lysophosphatidylcholine or a preparation thereof in preparation of medicaments for treating and / or repairing spinal cord injury and related diseases thereof. The lysophosphatidylcholine 18: 0 can enhance neuronal differentiation in vivo and in vitro, and effectively promote physiological and functional recovery after spinal cord injury. And the LPC18: 0 can be massively synthesized in a chemical mode and is easy to obtain. When being used for treating SCI (spinal cord injury), the medicine solves the problems of difficulty in obtaining NSC, poor batch stability, immune rejection reaction and the like, has the effect equivalent to that of NSC transplantation treatment, is safer and more economical, and has a good application prospect in the aspect of treating and / or repairing spinal cord injury.

The invention discloses a metabolic marker for diagnosing lung function grading in a stable phase of chronic obstructive pulmonary disease and application of the metabolic marker. According to the invention, in a training set, the lysophosphatidylcholine (17: 0 / 0: 0) is combined with the dimethylglycine or the lysophosphatidylcholine (17: 0 / 0: 0), the dimethylglycine is combined with the L-pyroglutamic acid or the lysophosphatidylcholine (17: 0 / 0: 0), the dimethylglycine is combined with the 5-hydroxyindoleacetic acid or the lysophosphatidylcholine (17: 0 / 0: 0), and the dimethylglycine is combined with the L-pyroglutamic acid or the lysophosphatidylcholine (17: 0 / 0: 0). The combination of the L-pyroglutamic acid and the 5-hydroxyindoleacetic acid has excellent diagnosis efficiency in diagnosing and distinguishing lung function 1-2 level and 3-4 level patients of the chronic obstructive pulmonary disease in the stable phase; further, verification results in a verification set show that the four combined metabolic markers have excellent accuracy in combined diagnosis and distinguishing of patients with the lung functions of the chronic obstructive pulmonary disease at the 1-2 level and the 3-4 level in the stable phase. Therefore, the four combined metabolic markers have the prospect of being developed into a kit for diagnosing and distinguishing lung function 1-2 level and 3-4 level patients of the stable-phase chronic obstructive pulmonary disease.

The invention relates to a preparation method of coenzyme Q10 and lysophosphatidylcholine, in particular to a method for preparing coenzyme Q10 and lysophosphatidylcholine from coenzyme Q10 ferment powder, and aims to solve the problem that coenzyme Q10 and lysophosphatidylcholine cannot be prepared from coenzyme Q10 ferment powder at the same time in the prior art. And the separation and purification of the coenzyme Q10 generally need to use a large amount of organic solvent, and silica gel waste is generated. According to the preparation method disclosed by the invention, the coenzyme Q10 zymophyte powder is subjected to enzymolysis reaction through phospholipase A, and then the coenzyme Q10 and the lysophosphatidylcholine are respectively extracted after reflux extraction and solid-liquid separation, so that the coenzyme Q10 zymophyte powder is fully utilized, the comprehensive utilization rate of the coenzyme Q10 zymophyte powder is improved, and the waste of raw materials is avoided.

The invention discloses a preparation for improving sensitivity of bacteria to kanamycin, and belongs to the technical field of medicine. The natural molecular compound lysophosphatidylcholine and the antibiotic kanamycin are jointly applied to antibiosis, and the antibacterial rate after the lysophosphatidylcholine and the kanamycin are combined is obviously higher than that of single kanamycin, so that the lysophosphatidylcholine is proved to improve the antibacterial activity of the kanamycin; the research view of the field of antibacterial drugs is widened, a new thought is provided for solving the problem of bacterial drug resistance, and the increasingly severe problem of bacterial drug resistance can be solved.

The invention discloses a preparation method of a hydrogenated lysolecithin-entrapped whitening composition and application of the hydrogenated lysolecithin-entrapped whitening composition in preparation of cosmetics, and provides a synergistic ratio of pterostilbene and tetrahydromagnolol which are whitening active matters, a nano entrapment technology is adopted, hydrogenated lysolecithin is used as a main emulsifier, and the hydrogenated lysolecithin-entrapped whitening composition is prepared into a cosmetic. The proper co-emulsifier and polyol are searched to entrap the grease which efficiently dissolves the whitening active matter into a stable nano-emulsion, so that pterostilbene and tetrahydromagnolol can permeate into the deep layer of the skin to play an efficient mild whitening role.

The present invention relates to a high-LPI lysolecithin and methods related to the same. The high-LPI product is produced through the reaction of lecithin with a unique method using solvent, buffer / water, and phospholipase. Using the current production method, LPI content increased from 1.4% to 3.2-13.1% using regular soy lecithin as the starting material and LPC, LPE and LPA contents also increased from 5.1%, 2.0%, 1.0% to 15.8%, 14.6% and 4.4% respectively.

[Problem] To provide an oil-in-water type emulsified food which can feel the mellow feeling of egg yolk and can suppress the fishy smell of egg yolk. [Solution] The present invention is an oil-in-water type emulsified food product containing at least egg yolk, the egg yolk content being 10-35 mass% relative to the total amount of the oil-in-water type emulsified food product, the phospholipid in the oil-in-water type emulsified food product containing at least one of phosphatidylcholine and lysophosphatidylcholine, and the oil-in-water type emulsified food product containing at least one of phosphatidylcholine and lysophosphatidylcholine. The total content of the phosphatidylcholine and the lysophosphatidylcholine is 2.0-4.0 mass% relative to the total amount of the oil-in-water type emulsified food, and the total content of the phosphatidylcholine and the lysophosphatidylcholine is 65 mass% or more relative to the total amount of the phospholipid.